Wasan HS et al. – In the current study, the addition of selective internal radiotherapy (SIRT) to first-line FOLFOX chemotherapy in liver-only and liver-dominant metastatic colorectal cancer patients did not improve overall survival compared with FOLFOX alone.

Methods

• Chemotherapy-naive patients with metastatic colorectal cancer (WHO PS 0 or 1) with liver metastases not suitable for curative resection or ablation were randomly assigned to oxaliplatin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and oxaliplatin [n=554]) or FOLFOX plus single treatment SIRT (n=549) concurrent with cycle 1 or 2 of chemotherapy.
• The primary endpoint was OS.

Results

• There were 411 deaths in 549 patients in the FOLFOX alone group and 433 deaths in 554 patients in the FOLFOX plus SIRT group (HR= 1.04).
• The median survival time in the FOLFOX plus SIRT group was 22.6 months compared with 23.3 months in the FOLFOX alone group.